The United Kingdom will become the first country to require continuous monitoring of AI-based medical devices after approval, moving away from one-time safety checks. The UK government accepted all 44 recommendations from a regulatory report and plans to publish a full National Health Service implementation plan by spring 2027. MHRA Chief Executive Lawrence Tallon noted that other nations are looking to the UK as it addresses complex, evolving non-deterministic algorithms.
Post-market monitoring of AI devices
- ▪The Medicines and Healthcare products Regulatory Agency will begin accepting applications for the third phase of its AI Airlock program, focusing on post-market surveillance and lifecycle monitoring.
- ▪The UK government will require constant monitoring of AI-based medical devices after approval rather than relying on a single pre-approval safety check.
Implementation plan for regulations
- ▪The UK government's implementation plan will specify delivery targets and timelines for deploying the regulatory changes across the National Health Service.
- ▪The UK government committed to publishing a full implementation plan for the AI medical device regulations by spring 2027, with a draft plan expected by the end of 2026.
International leadership in AI regulation
- ▪The United Kingdom is the first country to develop comprehensive rules for regulating artificial intelligence in medical devices.
- ▪Medicines and Healthcare products Regulatory Agency Chief Executive Lawrence Tallon stated on September 29, 2026, that multiple nations are approaching the United Kingdom to learn from its AI medical device rules.
Debatable claims
- ▪Continuous regulatory monitoring of AI medical devices will stifle healthcare innovation
- ▪The NHS lacks the capacity to effectively implement continuous AI monitoring regulations
- ▪The UK's early regulation of AI medical devices risks isolating its domestic market
- ▪The UK should mandate continuous post-market monitoring for AI-based medical devices
Story comments
Loading comments…